Why Voices for Psychedelic Policy Change Are Getting Louder in Michigan

The city of Ann Arbor recently held its first Entheofest event. The festival is a commemoration of the city’s measure to decriminalize entheogenic fungi and plants, which was approved last year. The event featured speeches from activists, martial artists, musicians, healers, therapists, artists, community leaders, elected officials and researchers who discussed various topics, including research, health and the history of psychedelics.

In an interview, codirector of Michigan’s Decriminalize Nature chapter Julie Barron stated that maintaining a personal relationship with entheogenic fungi and plant was a human right.

Organizers noted that the festival was an opportunity to advocate for the legalization and decriminalization of psychedelics as well as for people to share how these substances had helped them when other prescription drugs would not.

Nine other cities in the state of Michigan have begun decriminalization campaigns, since the city of Ann Arbor passed its decriminalization measure.

On Election Day, a measure to decriminalize the use of entheogenic fungi and plants in Detroit, dubbed Proposal E, was approved by city voters. The entheogenic substances decriminalized in the city include psilocybin from specific mushrooms with vision-producing capabilities, mescaline and peyote from specific cacti, ibogaine from Africa and ayahuasca from South America.

Similar to the cannabis decriminalization wave that has spread through the country, various states and cities are enacting decriminalization measures for psychedelic substances. Currently, however, the substances remain illegal at the federal level. These substances are classified as Schedule 1 drugs under the Controlled Substances Act by the DEA. Other drugs in this classification include cocaine, heroin, LSD and cannabis.

The act has five levels of classification, with substances under Schedule 1 being considered as drugs with the highest potential for abuse and addiction. Substances under Schedule 5 are considered to have the lowest potential for abuse and additions; those include cough syrup and briviact.

Last year, voters in the state of Oregon approved a ballot initiative that eliminated the hefty penalties imposed on the noncommercial personal possession of controlled substances. Earlier this year, Rhode Island also approved a measure that allowed a pilot program to establish harm reduction centers where individuals can safely consume controlled substances under the supervision of trained professionals.

In addition, New Jersey approved a measure to decriminalize the possession of less than one ounce of hallucinogenic mushrooms. Washington DC, Seattle and Denver, along with the city councils of Cambridge, Somerville and Northampton in the state of Massachusetts, and the cities of Arcata, Santa Cruz and Oakland in California have decriminalized the use of entheogenic fungi and plants.

The calls for change reflect the growing awareness about psychedelics as leading sector players such as Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF) conduct studies aimed at developing breakthrough therapies from these substances.

NOTE TO INVESTORS: The latest news and updates relating to Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF) are available in the company’s newsroom at https://ibn.fm/DELCF

About PsychedelicNewsWire

PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.

To receive instant SMS alerts, text “Groovy” to 888-902-4192 (U.S. Mobile Phones Only)

For more information please visit https://www.psychedelicnewswire.com

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.psychedelicnewswire.com/Disclaimer

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
www.psychedelicnewswire.com
415.949.5050 Office
Editor@PsychedelicWire.com

PsychedelicNewsWire is part of the InvestorBrandNetwork.